Evidence map›Paper›PMID 37110589›Full record

ArticleMolecules (Basel, Switzerland)2023

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents.

Han-Xu Li, Jian-Hui Tian, Hua-Yu Li, Xin Wan, Yu Zou

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Han-Xu LiInstitute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupationl Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
Jian-Hui TianInstitute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupationl Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.ORCID 0000-0002-9121-4244
Hua-Yu LiInstitute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupationl Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
Xin WanInstitute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupationl Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
Yu ZouInstitute of Pharmaceutical Process, Hubei Province Key Laboratory of Occupationl Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.ORCID 0000-0002-8812-5662
Wuhan University of Science and Technology · CN

Funding

College Students' innovative Entrepreneurial Training Plan Program of Hubei province S201910488066National Natural Science Foundation of China Grant NO. 82003593Natural Science Foundation of Hubei Province of China Grant NO. 2019CFB104
6 · The paper itself

Abstract

Antiplatelet aggregation agents have demonstrated clinical benefits in the treatment of ischemic stroke. In our study, a series of novel nitric oxide (NO)-donating ligustrazine derivatives were designed and synthesized as antiplatelet aggregation agents. They were evaluated for the inhibitory effect on 5'-diphosphate (ADP)-induced and arachidonic acid (AA)-induced platelet aggregation in vitro. The results showed that compound

Indexed as

Nitric OxidePlatelet Aggregation InhibitorsArachidonic AcidPlatelet AggregationPyrazinesStructure-Activity RelationshipArachidonic AcidNitric OxidePlatelet Aggregation InhibitorsPyrazinestetramethylpyrazineantiplatelet aggregation agentsligustrazinenitric oxide donorsstructure-activity relationships

Identifiers

PMID37110589
PMCPMC10144142
OpenAlexW4363651621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.